Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| CP CPRXCatalyst Pharmaceutical | $31.49+0.0% | $3.85B | 3 assetsStage unavailable | No dated catalyst | |
| CR CRBPCorbus Pharmaceuticals | $10.38+5.5% | $200.8M | 7 assetsPhase 1b | CRB-913Phase 1b · Data readout | |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
| $1.66+3.1% |
| $178.0M |
4 assetsPhase 1 |
CB-011Phase 1 · Data readout |
| CR CRDFCardiff Oncology, Inc. | $0.88-3.1% | $68.5M | 8 assetsStage unavailable | No dated catalyst |
| CR CRDLCardiol Therapeutics | $1.86-1.3% | $217.3M | 3 assetsStage unavailable | No dated catalyst |
| CR CRISCuris | $1.58-1.9% | $3.8M | 9 assetsPhase 2 | Emavusertib (CA-4948) (IRAK4/FLT3 Inhibitor)Phase 2 · Data readout |
| CR CRMDCorMedix | $8.20-0.4% | $639.1M | 3 assetsStage unavailable | No dated catalyst |
| CR CRNXCrinetics | $84.69+0.0% | $8.99B | 8 assetsStage unavailable | No dated catalyst |
| CR CRSPCRISPR Therapeutics | $59.50+2.4% | $5.75B | 22 assetsPhase 2 | CTX112Phase 1 · Data readout |
| CR CRVSCorvus | $14.46+0.9% | $1.22B | 10 assetsPhase 3 | Soquelitinib (CPI-818) Phase 3 · Data readout |
| CS CSCICOSCIENS Biopharma | $2.72+0.0% | $8.6M | 2 assetsStage unavailable | No dated catalyst |
| CT CTICCTI BioPharma | $9.09+0.0% | — | 1 assetsStage unavailable | No dated catalyst |
| CT CTMXCytomX Therapeutics | $3.28-0.3% | $714.7M | 11 assetsPhase 1 | CX-2051Phase 1 · Data readout |
| CT CTNMContineum Therapeutics Inc. | $17.19+7.3% | $646.7M | 5 assetsStage unavailable | No dated catalyst |
| CT CTXRCitius Pharmaceuticals | $0.60+0.1% | $16.5M | 5 assetsStage unavailable | No dated catalyst |
| CU CUECue Biopharma | $23.98-2.6% | $174.2M | 5 assetsPhase 2 | CUE-221 (Anti-IgE Antibody)Phase 2 · Data readout |
| CV CVACCureVac | $4.66+0.0% | $1.05B | 5 assetsStage unavailable | No dated catalyst |
| CV CVKDCadrenal Therapeutics | $1.61+0.6% | $5.7M | 5 assetsStage unavailable | No dated catalyst |
| CV CVMCel-Sci Corporation | $1.42-2.7% | $25.0M | 1 assetsStage unavailable | No dated catalyst |
| CY CYBNCybin | $8.28+1.2% | $413.1M | 2 assetsPhase 3 | CYB003 (Deuterated Psilocin Oral)Phase 3 · Data readout |
| CY CYCNCyclerion Therapeutics | $3.89-4.4% | $18.2M | 6 assetsStage unavailable | No dated catalyst |
| CY CYDYCytoDyn Inc | $0.21+0.0% | $287.6M | 7 assetsStage unavailable | No dated catalyst |
| CY CYTKCytokinetics Inc | $76.84-0.4% | $10.68B | 9 assetsApproved | AficamtenPhase 3 · Data readout |
| CY CYTOAltamira Therapeutics Ltd | $0.30-25.9% | — | 1 assetsStage unavailable | No dated catalyst |
| DA DAREDaré Bioscience, Inc. | $0.82+1.3% | $15.9M | 11 assetsPhase 3 | Ovaprene®Phase 3 · Data readout |
| DA DAWNDay One Pharmaceuticals | $21.53+0.0% | $2.22B | 5 assetsPhase 3 | Emi-Le/Emiltatug Ledadotin (Emi-Le) (B7-H4 ADC)Phase 1 · Data readout |
| DB DBTXDecibel Therapeutics | $4.91+0.0% | — | 2 assetsStage unavailable | No dated catalyst |
| DB DBVTDBV Technologies | $14.55+2.2% | $914.4M | 3 assetsStage unavailable | No dated catalyst |
| DC DCPHDeciphera Pharmaceuticals | $25.59+0.0% | $2.21B | 8 assetsStage unavailable | No dated catalyst |
| DC DCTHDelcath Systems Inc | $17.14+2.3% | $594.7M | 7 assetsPhase 2 | HEPZATO™Phase 2 · Data readout |
| DE DERMJourney Medical Corporation | $7.75+3.5% | $218.7M | 1 assetsStage unavailable | No dated catalyst |
| DF DFTXDefinium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) | $44.91-1.1% | $6.03B | 4 assetsPhase 3 | DT120 (formerly MM120; lysergide D-tartrate)Phase 3 · Data readout |
| DM DMACDiaMedica Therapeutics | $6.52+0.0% | $351.6M | 5 assetsPhase 2/3 | Rinvecalinase Alfa (DM199) (KLK1 Protein)Phase 2 · Data readout |
| DM DMKDMK Pharmaceuticals | $0.23+0.0% | — | 6 assetsStage unavailable | No dated catalyst |
| DN DNLIDenali Therapeutics | $24.92-0.1% | $3.98B | 15 assetsApproved | BIIB122 (DNL151)Phase 2a · Data readout |
| DN DNTHDianthus Therapeutics | $111.10+1.5% | $6.21B | 8 assetsPhase 3 | Claseprubart (DNTH103)Phase 2 · Data readout |
| DR DRMADermata Therapeutics | $1.42+2.9% | $7.0M | 5 assetsStage unavailable | No dated catalyst |
| DR DRRXDURECT Corporation | $1.91+0.0% | $59.3M | 2 assetsStage unavailable | No dated catalyst |
| DR DRUGBright Minds Biosciences | $77.42-1.5% | $759.6M | 3 assetsPhase 2 | No dated catalyst |
| DS DSGNDesign Therapeutics | $14.99-3.7% | $938.1M | 3 assetsPhase 2 | DT-216P2Phase 1/2 · Data readout |